Innovative Industrial Properties Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw revenue rise 3.5% to $69M and AFFO steady at $53.4M, with strong leasing activity and major regulatory progress for medical cannabis. Liquidity and credit metrics remain robust, and management expects further growth as refinancing and strategic investments proceed.
Fiscal Year 2025
-
2025 saw strong operational execution, robust liquidity, and strategic investments, with significant progress re-tenanting non-performing assets and expanding in both cannabis and life science sectors. AFFO and revenues improved, and regulatory developments are expected to further support growth.
-
Q3 revenue rose 3% to $64.7M, with AFFO steady at $1.71/share. A $105M IQHQ investment and new $100M credit facility diversify growth into life sciences. About 20% of ABR is not rent-paying, but legal and leasing progress is ongoing.
-
Q2 revenue and AFFO fell 12% sequentially due to tenant defaults, but liquidity and balance sheet remain strong. A $270M investment in IQHQ diversifies the portfolio and is expected to be highly accretive, while legal actions continue to address cannabis tenant issues.
-
Q1 2025 revenue fell 6.5% sequentially to $71.7M, with AFFO down 13% to $55.3M, mainly due to tenant defaults. Management is actively retenting properties, pursuing legal remedies, and maintaining strong liquidity, while monitoring macro and industry risks.
Fiscal Year 2024
-
Generated $308.5M in 2024 revenue with strong liquidity and 98% portfolio occupancy. AFFO declined slightly due to tenant rent issues, but management remains optimistic on industry growth and regulatory progress. Tenant risk and illicit market challenges persist.
-
Q3 2024 saw $76.5M in revenue and $2.25 AFFO/share, with strong liquidity and a 95.7% leased portfolio. Despite industry headwinds and some tenant rent issues, the outlook remains positive with a robust pipeline and anticipated regulatory progress.
-
Q2 2024 saw 4% revenue growth year-over-year, strong AFFO, and a 4.4% dividend increase, supported by robust re-leasing and disciplined investments. Liquidity and credit metrics remain industry-leading, with optimism for growth in new and expanding cannabis markets.